100% found this document useful (1 vote)
299 views59 pages

Antiulcer Drug Overview and Treatment

Peptic ulcer disease involves breaks in the mucosal surface of the gastrointestinal tract, primarily caused by an imbalance between aggressive and defensive factors, with common causes including H. pylori and NSAIDs. The document outlines the types of peptic ulcers, their pathogenesis, clinical features, and treatment options including H2 antagonists and proton pump inhibitors. It also discusses risk factors, associations, and the importance of specific drug regimens for effective management.

Uploaded by

Габи С.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd
100% found this document useful (1 vote)
299 views59 pages

Antiulcer Drug Overview and Treatment

Peptic ulcer disease involves breaks in the mucosal surface of the gastrointestinal tract, primarily caused by an imbalance between aggressive and defensive factors, with common causes including H. pylori and NSAIDs. The document outlines the types of peptic ulcers, their pathogenesis, clinical features, and treatment options including H2 antagonists and proton pump inhibitors. It also discusses risk factors, associations, and the importance of specific drug regimens for effective management.

Uploaded by

Габи С.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PPTX, PDF, TXT or read online on Scribd

Peptic ulcer disease

What is PEPTIC ULCER?????

 Breaks in mucosal surface


 >5mm in size
 Depth till submucosa
 In any part of GI tract exposed to aggressive
action of acid pepsin juices.
 Can be acute or chronic
 Both can penetrate muscularis mucosae..
SITES

 Gastric and duodenal – 98 %


 Ratio of 1:4
 Duodenum:1st part >95% :ant & post walls
 Gastric :junction b/w antrum &acid secr. mucosa :lesser curvature
Why Peptic ulcer occurs
?
 Imbalance between Aggressive factors and
Defensive factors
Regulation of gastric acid secretion
ETIOLOGY

 Predisposing factors
– Age :young in DU and GU.
– Sex :GU commoner in males
 Causes
– [Link]
– NSAID
– Infection: herpes simplex,etc..
– Other drug/toxin: bisphosphonates ,glucocorticoids
Pathogenetic factors not related to
[Link] & NSAID
 Smoking
 Genetic : blood group O
 Stress
 Diet : alcohol and caffeine
Associations

 Systemic mastocytosis
 Nephrolithiasis
 Hyperparathyroidism
 Cirrhosis
 Alpha antitrypsin deficiency
 Pancreatitis, polycythaemia vera
Pathogenesis
 Related with NSAIDs

NSAIDs migrate across lipid membrane of epithelial cells.

Trapped in an ionized form

Related with NSAIDs Cell injury

 Topical NSAIDs.

Alter surface mucous layer.

Peronits back diffusion of H+ & Pepsin.

Further cell damage.


Figure shows machanisms by which
NSAIDs may induce mucosal injury :
Risk factors for NSAID – induced
Gastroduodenal ulcers
 Established  Possible
 Advanced age.  Concomitant infection with H. pylori.
 History of ulcer.  smoking.
 Concomitant use of glucocorticoids.  Alcohol consumption.
 High dose of NSAIDs.
 Multiple NSAIDs.
 Concomitant use of anticoagulants
serious or multi system disease.
Phathogenesis of [Link]
Types of peptic ulcer

Acute peptic ulcer


Chronic peptic ulcers
- Gastric ulcers
- Duodenal ulcer
Acute peptic ulcer

 Ingestion of Aspirin or butazolidin.


 By stress (Stress ulcer):-
 May be following endotoxic
shock :
-Hypotension,
-Hemorrhage or
-Cardiac infarction
Acute peptic ulcer
 Sepsis.
 After trauma or neurosurgical operations (Curling’s ulcers).
 After burns (curling’s ulcers).
 Patient on steroids

The size of peptic ulcer (Steroids ulcers).


CHRONIC PEPTIC ULCERS
 GASTRIC ULCERS
 . Decrease mucosal resistance.
 . Pyloroduodenal reflex.
 . Deficient mucous barriers.
 . Mucosal trauma.
 . Local Ischaemia.
 . Antral stasis.
 . NSAIDs.
 . Helicobacter pylori.
DUODENAL ULCER

 Acid hyper secretion.


 . Genetics factor.
 . Endocrine organ dysfunction.
 . Liver abscess.
 . Emotional factors.
 . Diet & smoking.
 . Helicobacter pylori.
 . Decrease in bicarbonate production.
Pathophysiology Gastric ulcer Duodenal ulcer

Major causes [Link] & NSAID [Link] & NSAID

Gastric acid decreased increased

Gastric emptying delayed rapid

Abnormal resting & stimulated Bicarbonate secretion remarkably


Pyloric sphincter pressure decreased
Clinical features
 Abdominal pain*
•Epigastric
•Burning or discomfort
•Awakes from sleep
 Nausea
 Weight loss
 Dyspepsia if not relieved by antacids —penetrating ulcer
Treatment ?
H2 ANTAGONISTS
Mechanism of action

 Competitively block H2 receptors on parietal


cell & inhibit gastric acid production
 Suppress secretion of acid in all phases but
mainly nocturnal acid secretion
 Also reduce acid secretion stimulated by
Ach, gastrin, food, etc.
Pharmacokinetics

 Absorption is not interfered by food


 Can cross placental barrier and reaches milk, Poor CNS
penetration
 The serum half-lives range from 1.1 to 4 hours;
 Cleared by a combination of hepatic metabolism, glomerular
filtration, and renal tubular secretion.
 Dose reduction needed in moderate to severe renal
insufficiency
Comparison of H2 antagonists
H2 antagonists - Uses

Promote the healing of gastric and duodenal ulcers


 Duodenal ulcer – 70 to 90% at 8 weeks
 Gastric Ulcer – 50 to 75%
 NSAID ulcers induced ulcers
 Stress ulcer and gastritis
 GERD
 Zollinger-Ellison syndrome
 Prophylaxis of aspiration pneumonia
Adverse effects

 Headache, dizziness, bowel upset, dry mouth


 CNS: Confusion, restlessness

Bolus IV – release histamine –
bradycardia, arrhythmia, cardiac arrest
 Cimetidine has antiandrogenic actions
Proton Pump Inhibitors

 Most effective drugs in antiulcer therapy


 Prodrugs requiring activation in acid environment
 Activated forms binds irreversibly to H+K+ATPase and
inhibit it
Omeprazole
Pantoprazole
Lansoprazole
Esomeprazole
Mechanism of Action

 Prodrugs inactive at neutral pH



At pH < 5 rearranges to two charged
cationic forms (sulfenamide + sulphenic acid)
that bind covalently with SH groups of H⁺K⁺
ATPase and inactivate it irreversibly

Also inhibits gastric mucosal
carbonic anhydrase
Pharmacokinetics - PPI

 Available as enteric coated tablets



They should be given 30 minutes to 1 hour
before food intake
 half life is very short and only 1-2 Hrs

Still the action persists for 24 Hrs to 48 hrs
after a single dose

Action lasts for 3-4days even after stoppage of
the drug
Therapeutic uses:

 1. Gastroesophageal reflux disease (GERD)


 2. Peptic Ulcer - Gastric and duodenal ulcers
 3. Bleeding peptic Ulcer
 4. Zollinger Ellison Syndrome
 5. Prevention of recurrence of nonsteroidal antiinflammatory drug (NSAID)
- associated gastric ulcers in patients who continue NSAID use.
 6. Reducing the risk of duodenal ulcer recurrence associated with H.
pylori
infections
 7. Aspiration Pneumonia
Adverse Effects

 Nausea, loose stools, headache abdominal


pain, constipation,
 Muscle & joint pain, dizziness, rashes
 Rare :
Gynaecomastia, erectile dysfunction
Leucopenia and hepatic dysfunction
Osteoporosis in elderly on prolonged use
Hypergastrinemia
Drug interactions


Omeprazole inhibits the metabolism
of warfarin, phenytoin, diazepam, and
cyclosporine.

However, drug interactions are not a
problem with the other PPIs.
PPI – Dosage schedule

 Omeprazole - 20 mg o.d.
 Lansoprazole - 30 mg o.d.
 Pantoprazole - 40 mg o.d.
 Rabeprazole - 20 mg o.d.
 Esomeprazole - 20-40 mg o.d
Proton Pump Inhibitors

 Lansoprazole :
Partly reversible, more potent, slightly more against
[Link], Higher BA, rapid onset.
 Pantoprazole:
More acid stable, I.V, CYP450 less affinity
 Rabeprazole:
claimed to most rapid
 Es-omeprazole
Better intragastric pH , higher healing rates.
Antacid - Interactions

 Absorb drugs and form insoluble complexes that are


not absorbed


Clinical importance : Interactions can be avoided
by taking antacids 2 hrs before or after ingestion of
other drugs .
Now answer this question

Is it rational to combine Aluminium


hydroxide and Magnesium hydroxide
in antacid preparations ?
Systemic antacids

 • Soluble instant short duration


 • But cause systemic alkalosis
 • So other uses
– Metabolic acidosis
– Alkalinisation of urine
– Antipruritic lotion,eye wash,mouth wash
Adverse effects

 constipation,
 hypophosphatemia
• Other uses
–Bile reflux Gastritis Stomatitis
–Prophylaxis of stress ulcers
US FDA Approved Regimen

• Lansoprazole 30mg
• Amoxicillin 1000mg
• Clarithromycin 500mg

Twice daily Two weeks


Quadruple Therapy

 Given when Triple Therapy fails


 CBS - 120 mg qid
 Omeprazole / Lansoprazole - 20 / 30 mg bd
 Metronidazole - 400 mg TDS Tetracycline - 500 mg
qid
Thank
You

You might also like